BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 708K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now
Advanced Search

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

13 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Fatty Acid Transport Proteins: Targeting FATP2 as a Gatekeeper Involved in the Transport of Exogenous Fatty Acids.EBI
University of Nebraska
Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors.EBI
University of Nebraska
A set of phosphatase-inert"molecular rulers" to probe for bivalent mannose 6-phosphate ligand-receptor interactions.EBI
University of Nebraska
The evolution of small molecule enzyme activators.EBI
University of Nebraska
CitA activity is modulated by cysteine oxidation and pyruvate binding.EBI
University of Nebraska
Discovery, synthesis and biological characterization of a series of EBI
University of Nebraska
Cysteine protease inhibitors and methods of use thereofBDB
Anixa Biosciences
Salt of fused pyrimidine compound and crystal thereofBDB
Taiho Pharmaceutical
Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamideBDB
Exelixis
2-Aryl-N-acyl indole derivatives as liver X receptor (LXR) agonists.BDB
Tanabe Research Laboratories Usa
Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.BDB
Abbott Laboratories
The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors.BDB
Glaxosmithkline